36 results about "Opioid peptide" patented technology

The invention relates to a method for preparing a wheat protein source opioid peptide by the enzymolysis of wheat protein, belonging to the technical field of wheat protein deep processing. The method comprises the following steps of: taking wheat protein as raw material; then adding water to achieve a certain mass percent and regulating to a certain temperature and pH; firstly, adopting pepsin to carry out enzymolysis; then changing enzymolysis conditions; adopting trypsinase or trypsogen to carry out enzymolysis; regulating pH to be neutral after hydrolysis is ended; inactivating enzyme, cooling and centrifuging; taking supernate, and then decoloring, separating with a 3000Da ultra-filtration membrane and drying, and finally obtaining the wheat protein source opioid peptide. Adopting a guinea-pig ileum method to determine the opioid activity shows that the prepared wheat protein source opioid peptide has obvious opioid activity, whereas the wheat protein of the raw material does not have opioid activity. The invention widens the application range of the wheat protein through preparing the wheat protein source opioid peptide by enzymolysis, thereby providing the theoretical basis and efficient path for promoting the deep development and utilization of the wheat protein.

A method for examining a disease includes measuring plural opioid peptides or opioid receptors in blood cell, body fluid, or tissue and calculating the ratio thereof. The method can be specifically applied to pruritic diseases. The invented method for examination can determine whether opioids are involved in a pruritic disease and can determine whether therapy with an opioid agonistic and/or antagonistic antipruritus agent is appropriate or not.

PCT No. PCT/SE97/02156 Sec. 371 Date Apr. 1, 1998 Sec. 102(e) Date Apr. 1, 1998 PCT Filed Dec. 18, 1997 PCT Pub. No. WO98/28327 PCT Pub. Date Jul. 2, 1998Use of a compound of the formula I for the manufacture of a medicament for the treatment of pain. The compounds are delta opioid agonists and thus useful in the treatment of pain without the requirement of co-application of a mu opioid agonist.

The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergilius melleus, and exhibits a degradation activity for a wheat gluten-derived opioid peptide and a casein-derived opioid peptide.

The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumours.

An object of the present invention is to provide an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide that does not restrict dietary habits, does not provide side reactions, even if it is daily used, and thus can be continuously used without any worries. The object is achieved by an agent for decomposing an opioid peptide or composition for decomposing an opioid peptide, pharmaceutical composition for decomposing an opioid peptide, or food or drink composition for decomposing an opioid peptide containing a Bifidobacterium bacterium, a culture of the bacterium, and/or a processed cell product of the bacterium as an active ingredient.

The invention discloses a bifunctional peptide based on opioid peptide and cannabis sativa peptide as well as a preparation method and application thereof. The bifunctional peptide is a brand-new bifunctional peptide constructed based on an N-terminal sequence of opioid peptide DALDA and a C-terminal sequence of cannabis sativa peptide (m) VD-Hpalpha-NH2. Compared with the prior art, the analgesic activity of OCP 001 and OCP 002 in vivo is enhanced, an analgesic effect which is more effective than that of parent molecules is generated, the problem of analgesic tolerance existing in opioid and hemp agonists and the parent molecules is solved, an analgesic effect in a non-tolerance form is generated, and the bifunctional peptide can be used for treating acute pain and pathological pain.

The invention discloses a difunctional D-amino acid modified opioid peptide compound, a synthesis method of the compound and application of the series of analogues to preparation of analgesics. The synthesis method comprises the steps of synthesizing solid-phase carrier peptide resin; on the solid-phase carrier, sequentially inoculating corresponding amino acid according to the sequence from a C end to an N end of a polypeptide sequence; and performing peptide resin after treatment, cutting peptide, extracting peptide and performing preparation and purification. The synthesis method is simpleand convenient, easy to operate, short in condensation time, capable of perform large-scale synthesis and easy in purification. Sites, which are easily identified by enzyme and subjected to digestion,in a modified sequence are selectively replaced, high mu-opioid receptor can be maintained, the ability of resisting hydrolysis of enzyme in a living body can be obviously improved, the duration timeof analgesic activity and analgesic effect is prolonged, the bioavailability is effectively improved, and good pharmacological activity and potential clinical application value are achieved.

The invention discloses an active fragment of an anti-opioid peptide and an antagonistic peptide and application thereof. The anti-opioid peptide is one of the following amino acid residue sequences: 1) SEQ ID No:1 in a sequence list; 2) SEQ ID No:3-5; and 3) a polypeptide which has an antagonistic morphine damage resisting function and is formed by substituting, deleting or adding one to ten amino acid residues in the amino acid residue sequence of SEQ ID No:1 and SEQ ID No:3-5 in the sequence list. The antagonistic peptide is one of the following amino acid residue sequences: 1) SEQ ID No:9-11 in the sequence list; and 2) a polypeptide which has functions of enhancing morphine analgesis, reversing morphine resistance and/or weakening or eliminating withdrawal symptoms and is formed by substituting, deleting or adding one to ten amino acid residues in the amino acid residue sequence of SEQ ID No:9-11 in the sequence list. The anti-opioid peptide and the active fragment and antagonistic peptide of the anti-opioid peptide can play important roles in the field of medicine or the field of the preparation of rehabilitation medicaments and have wide application prospect.

The invention discloses anti-opioid peptide, and antagonistic peptide and application thereof. The anti-opioid peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:1 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:1 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effect of resisting morphine damages. The antagonistic peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:5-7 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:5-7 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effects of enhancing morphine analgesia, reversing morphine tolerance and/or weakening or eliminating abstinence syndromes. The anti-opioid peptide and an active segment and the antagonistic peptide thereof exert an important effect in the field of preparation of medicinal and drug treatment medicaments and have wide application prospects.

The present invention provides the use of Entauren in the preparation of drugs for detoxification, that is, a new application of Entaurea for drug withdrawal; Entaurea is widely used as an early analgesic for acute trauma As well as drugs in operations and other invasive medical operations that require a short analgesic time, they have the advantages of being safe, effective, simple, economical, non-invasive, and can replace narcotic analgesics. They can activate the central nervous system and promote endogenous The release of opioid peptides can supplement the lack of endorphins released by the body due to long-term drug use. Old drugs are used for new purposes, and the scope of application can be broadened as a drug detoxification drug. At the same time, Antaile can also relieve the pain caused by withdrawal symptoms and relieve anxiety. Reduce acute sudden death caused by severe withdrawal symptoms, so that drug addicts can stay awake, relaxed, comfortable and cooperate with treatment without pain during the entire detoxification treatment process.